

PRIOR AUTHORIZATION CRITERIA

CLASS NAME	HIV INAPPROPRIATE COMBINATIONS/INTERACTIONS
------------	---

BRAND NAME (generic)

COMBINATION DRUGS:

ATRIPLA (efavirenz-emtricitabine-tenofovir disoproxil fumarate)
 BIKTARVY (bictegravir-emtricitabine-tenofovir alafenamide)
 CIMDUO (lamivudine-tenofovir disoproxil fumarate)
 COMBIVIR (lamivudine-zidovudine)
 COMPLERA (rilpivirine-emtricitabine-tenofovir disoproxil fumarate)
 DELSTRIGO (doravirine-lamivudine-tenofovir disoproxil fumarate)
 DOVATO (dolutegravir-lamivudine)
 EPZICOM (lamivudine-abacavir)
 EVOTAZ (atazanavir-cobicistat)
 GENVOYA (elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide)
 JULUCA (dolutegravir-rilpivirine)
 KALETRA (lopinavir-ritonavir)
 ODEFSEY (emtricitabine-rilpivirine-tenofovir alafenamide)
 PREZCOBIX (darunavir-cobicistat)
 STRIBILD (cobicistat-elvitegravir-emtricitabine-tenofovir disoproxil fumarate)
 SYMFI / SYMFI LO (efavirenz-lamivudine-tenofovir disoproxil fumarate)
 SYMTUZA (darunavir-cobicistat-emtricitabine-tenofovir alafenamide)
 TEMIXYS (lamivudine-tenofovir disoproxil fumarate)
 TRIUMEQ (abacavir-dolutegravir-lamivudine)
 TRIZIVIR (abacavir-lamivudine-zidovudine)

SINGLE INGREDIENT DRUGS:

APTIVUS (tipranavir)
 CRIXIVAN (indinavir)
 EDURANT (rilpivirine)
 EMTRIVA (emtricitabine)
 EPIVIR (lamivudine)
 INTELENCE (etravirine)
 ISENTRESS (raltegravir)
 NORVIR (ritonavir)
 PIFELTRO (doravirine)
 RESCRIPTOR (delavirdine)
 RETROVIR (zidovudine)
 REYATAZ (atazanavir)
 SUSTIVA (efavirenz)
 TYBOST (cobicistat)
 VIDEX (didanosine)
 VIRAMUNE (nevirapine)
 VIREAD (tenofovir disoproxil fumarate)
 ZERIT (stavudine)

Status: CVS Caremark Criteria

Type: Initial Prior Authorization

POLICY

PROGRAM DESCRIPTION

Plans implementing the HIV Inappropriate-Interaction hard stop DUR edit will ensure patients do not take antiretrovirals that interact with each other or are inappropriate to take together. The adjudication system will look back for the inappropriate or interacting agents within the past 15 days. If the patient has not filled an antiretroviral that interacts or is inappropriate to take with the requested drug within the past 15 days, then the requested drug will be paid under the prescription benefit. If the patient does not meet the initial look back, then the system will reject with a message ('Two inapprop.,interacting HIV drugs; PA required') indicating that a prior authorization (PA) is required. The post DUR criteria would then be applied to requests submitted for evaluation to the PA unit.

COVERAGE CRITERIA

The requested drug will be covered with prior authorization when the following criteria are met:

- The prescriber will evaluate the patient's regimen and discontinue interacting or inappropriate drug combination(s)

Inappropriate HIV Combination Therapy/Interactions Drug A + B (or Drug B + A) Chart		
Drug A	Drug B	Rationale
Atazanavir + Indinavir		<i>Atazanavir and indinavir can cause Grade 3 to 4 hyperbilirubinemia and jaundice.</i>
Evotaz (atazanavir-cobicistat) Reyataz (atazanavir)	Crixivan (indinavir)	
Emtricitabine + Lamivudine		<i>Emtricitabine and lamivudine have similar resistance profiles and have minimal additive antiviral activity.</i>
Atripla (efavirenz-emtricitabine-tenofovir) Biktarvy (bictegravir-emtricitabine-tenofovir) Complera (rilpivirine-emtricitabine-tenofovir) Emtriva (emtricitabine) Genvoya (elvitegravir-cobicistat-emtricitabine-tenofovir) Odefsey (emtricitabine-rilpivirine-tenofovir) Stribild (cobicistat-elvitegravir-emtricitabine-tenofovir) Symtuza (darunavir-cobicistat-emtricitabine-tenofovir)	Epivir (lamivudine) Cimduo (lamivudine-tenofovir) Combivir (lamivudine-zidovudine) Delstrigo (doravirine-lamivudine-tenofovir) Dovato (dolutegravir-lamivudine) Epzicom (lamivudine-abacavir) Symfi / Symfi Lo (efavirenz-lamivudine-tenofovir) Temixys (lamivudine-tenofovir) Triumeq (abacavir-dolutegravir-lamivudine) Trizivir (abacavir-lamivudine-zidovudine)	
Didanosine + Stavudine		<i>Didanosine and stavudine as a dual-NRTI backbone can result in a high incidence of toxicities, particularly peripheral neuropathy, pancreatitis, and lactic acidosis.</i>
Videx (didanosine)	Zerit (stavudine)	
Didanosine + Tenofovir Disoproxil Fumarate		<i>Tenofovir disoproxil fumarate (TDF) increases ddl (didanosine) concentrations, serious ddl-</i>

		<i>associated toxicities, immunologic nonresponse, early virologic failure, and resistance</i>
Videx (didanosine)	Viread (tenofovir disoproxil fumarate) Atripla (efavirenz-emtricitabine-tenofovir disoproxil fumarate) Cimduo (lamivudine-tenofovir disoproxil fumarate) Complera (rilpivirine-emtricitabine-tenofovir disoproxil fumarate) Delstrigo (doravirine-lamivudine-tenofovir disoproxil fumarate) Stribild (cobicistat-elvitegravir-emtricitabine-tenofovir disoproxil fumarate) Symfi / Symfi Lo (efavirenz-lamivudine-tenofovir disoproxil fumarate) Temixys (lamivudine-tenofovir disoproxil fumarate)	
Stavudine + Zidovudine		<i>Stavudine and zidovudine should not be used in combination because of antagonism demonstrated in vitro and in vivo.</i>
Zerit (stavudine)	Combivir (lamivudine-zidovudine) Retrovir (zidovudine) Trizivir (abacavir-lamivudine-zidovudine)	
Etravirine + Tipranavir (ritonavir-boosted)		<i>Tipranavir (ritonavir-boosted as a standard) significantly reduces etravirine concentrations.</i>
Intelence (etravirine)	Aptivus (tipranavir) (ritonavir boosted)	
Etravirine + Raltegravir (HD only)		<i>Concurrent use of etravirine and raltegravir may result in decreased plasma concentrations of raltegravir (HD only) and risk of diminished therapeutic effect of raltegravir (HD only).</i>
Intelence (etravirine)	Isentress (raltegravir) (HD only)	
Tipranavir(ritonavir-boosted) + Raltegravir (HD only)		<i>Tipranavir (ritonavir-boosted as a standard) and raltegravir (HD only) coadministration is not recommended</i>
Aptivus (tipranavir) (ritonavir boosted)	Isentress (raltegravir) (HD only)	
Two NNRTIs		<i>Two-non-nucleoside reverse transcriptase inhibitor (2-NNRTI) combinations can cause a higher frequency of clinical adverse events that leads to treatment discontinuation.</i>
Rilpivirine + another NNRTI		
Complera (rilpivirine-emtricitabine-tenofovir) Edurant (rilpivirine) Odefsey (emtricitabine-rilpivirine-tenofovir)	Atripla (efavirenz-emtricitabine-tenofovir) Delstrigo (doravirine-lamivudine-tenofovir) Intelence (etravirine)	

Juluca (dolutegravir-rilpivirine)	Pifeltro (doravirine) Rescriptor (delavirdine) Sustiva (efavirenz) Symfi / Symfi Lo (efavirenz-lamivudine-tenofovir) Viramune (nevirapine)	
Efavirenz + another NNRTI		
Atripla (efavirenz-emtricitabine-tenofovir) Sustiva (efavirenz) Symfi / Symfi Lo (efavirenz-lamivudine-tenofovir)	Complera (rilpivirine-emtricitabine-tenofovir) Delstrigo (doravirine-lamivudine-tenofovir) Edurant (rilpivirine) Intelence (etravirine) Juluca (dolutegravir-rilpivirine) Odefsey (emtricitabine-rilpivirine-tenofovir) Pifeltro (doravirine) Rescriptor (delavirdine) Viramune (nevirapine)	
Etravirine + another NNRTI		
Intelence (etravirine)	Atripla (efavirenz-emtricitabine-tenofovir) Complera (rilpivirine-emtricitabine-tenofovir) Delstrigo (doravirine-lamivudine-tenofovir) Edurant (rilpivirine) Juluca (dolutegravir-rilpivirine) Odefsey (emtricitabine-rilpivirine-tenofovir) Pifeltro (doravirine) Rescriptor (delavirdine) Sustiva (efavirenz) Symfi / Symfi Lo (efavirenz-lamivudine-tenofovir) Viramune (nevirapine)	
Delavirdine + other NNRTI		
Rescriptor (delavirdine)	Atripla (efavirenz-emtricitabine-tenofovir) Complera (rilpivirine-emtricitabine-tenofovir) Delstrigo (doravirine-lamivudine-tenofovir) Edurant (rilpivirine) Intelence (etravirine) Juluca (dolutegravir-rilpivirine) Odefsey (emtricitabine-rilpivirine-tenofovir) Pifeltro (doravirine) Sustiva (efavirenz) Symfi / Symfi Lo (efavirenz-lamivudine-tenofovir) Viramune (nevirapine)	

Nevirapine + another NNRTI		
Viramune (nevirapine)	Atripla (efavirenz-emtricitabine-tenofovir) Complera (rilpivirine-emtricitabine-tenofovir) Delstrigo (doravirine-lamivudine-tenofovir) Edurant (rilpivirine) Intelence (etravirine) Juluca (dolutegravir-rilpivirine) Odefsey (emtricitabine-rilpivirine-tenofovir) Pifeltro (doravirine) Rescriptor (delavirdine) Sustiva (efavirenz) Symfi / Symfi Lo (efavirenz-lamivudine-tenofovir)	
Doravirine + another NNRTI		
Delstrigo (doravirine-lamivudine-tenofovir) Pifeltro (doravirine)	Atripla (efavirenz-emtricitabine-tenofovir) Complera (rilpivirine-emtricitabine-tenofovir) Edurant (rilpivirine) Intelence (etravirine) Juluca (dolutegravir-rilpivirine) Odefsey (emtricitabine-rilpivirine-tenofovir) Rescriptor (delavirdine) Sustiva (efavirenz) Symfi / Symfi Lo (efavirenz-lamivudine-tenofovir) Viramune (nevirapine)	
Two Boosters		<i>Two booster agents can cause a higher frequency of clinical adverse events that leads to treatment discontinuation.</i>
Ritonavir + Cobicistat		
Kaletra (lopinavir-ritonavir) Norvir (ritonavir)	Evotaz (atazanavir-cobicistat) Genvoya (elvitegravir-cobicistat-emtricitabine-tenofovir) Prezcobix (darunavir-cobicistat) Stribild (cobicistat-elvitegravir-emtricitabine-tenofovir) Symtuza (darunavir-cobicistat-emtricitabine-tenofovir) Tybost (cobicistat)	

REFERENCES

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. Available at <http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf>. Accessed November 2020.